We are live on ! Find out more
TCM

Tamarack Capital Management Portfolio holdings

AUM $840M
1-Year Est. Return 19.47%
This Fund
S&P 500
This Quarter Est. Return
+1.16%
1 Year Est. Return
+19.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$490M
AUM Growth
+$89.3M
Cap. Flow
+$93.4M
Cap. Flow %
19.06%
Top 10 Hldgs %
72.93%
Holding
34
New
10
Increased
14
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$14.9M
2
SPNC
Spectranetics Corp
SPNC
+$14.5M
3
ELGX
Endologix Inc
ELGX
+$12.6M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$12.6M
5
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$10.4M

Top Sells

Rank Stock Value
1
INSY
Insys Therapeutics, Inc.
INSY
+$19.8M
2
BMR
BIOMED REALTY TRUST INC
BMR
+$11.3M
3
CNMD icon
CONMED
CNMD
+$6.44M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$3.36M
5
NXTM
NxStage Medical Inc.
NXTM
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 50.32%
2 Technology 2.54%
3 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$128M 26.16%
1,100,000
+900,000
+450% +$102M
CFN
2
DELISTED
CAREFUSION CORPORATION
CFN
$39.1M 7.99%
875,000
+175,000
+25% +$7.24M
VOLC
3
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$33.6M 6.86%
2,018,300
+373,300
+23% +$6.79M
ELGX
4
DELISTED
Endologix Inc
ELGX
$33.6M 6.86%
237,500
+95,000
+67% +$12.6M
SPNC
5
DELISTED
Spectranetics Corp
SPNC
$26.2M 5.35%
1,150,000
+625,000
+119% +$14.5M
ALKS icon
6
Alkermes
ALKS
$8.82B
$25.6M 5.22%
525,000
+50,000
+11% +$2.31M
COV
7
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$20.5M 4.18%
225,000
+50,000
+29% +$3.74M
AUXL
8
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$18.4M 3.75%
943,526
+18,526
+2% +$425K
ITGR icon
9
Integer Holdings
ITGR
$3.35B
$18M 3.67%
405,780
+21,830
+6% +$935K
NXTM
10
DELISTED
NxStage Medical Inc.
NXTM
$14.2M 2.9%
1,050,000
-150,000
-13% -$1.96M
TEVA icon
11
Teva Pharmaceuticals
TEVA
$35.9B
$13.3M 2.71%
+246,500
New +$12.6M
CTRX
12
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
$13M 2.66%
300,000
-25,000
-8% -$1.06M
MDXG icon
13
MiMedx Group
MDXG
$626M
$12.1M 2.47%
1,775,000
-25,000
-1% -$146K
AEGR
14
DELISTED
Aegerion Pharmaceuticals
AEGR
$11.7M 2.38%
+400,000
New +$14.9M
IRWD icon
15
Ironwood Pharmaceuticals
IRWD
$611M
$11.5M 2.35%
+955,200
New +$10.4M
ATRC icon
16
AtriCure
ATRC
$1.77B
$9.83M 2.01%
586,555
+164,263
+39% +$2.73M
SRGA
17
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$9.35M 1.91%
71,667
+5,000
+7% +$635K
VCRA
18
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$9.19M 1.88%
700,000
-100,000
-13% -$1.37M
PDCO
19
DELISTED
Patterson Companies, Inc.
PDCO
$8.86M 1.81%
+225,000
New +$9.1M
LMNX
20
DELISTED
Luminex Corp
LMNX
$8.29M 1.69%
500,000
+200,000
+67% +$3.52M
STRM
21
DELISTED
Streamline Health Solutions
STRM
$5.19M 1.06%
68,333
+10,000
+17% +$742K
CORI
22
DELISTED
Corium International, Inc.
CORI
$4.94M 1.01%
+627,670
New +$4.73M
NTUS
23
DELISTED
Natus Medical Inc
NTUS
$3.8M 0.78%
+153,533
New +$3.8M
IMPR
24
DELISTED
IMPRIVATA, INC COM
IMPR
$3.24M 0.66%
+195,553
New +$3.15M
WINT
25
DELISTED
Windtree Therapeutics Inc
WINT
$2.77M 0.57%
107,143
+35,714
+50% +$913K
1
2

Similar funds

RI
Relational Investors San Diego, California $840M AUM 0.57% 1-Year Est. Return
CWA
Constellation Wealth Advisors New York $903M AUM 2.38% 1-Year Est. Return
GHF
Good Harbor Financial Barrington, Illinois $916M AUM 5.96% 1-Year Est. Return
F
FutureAdvisor San Francisco, California $617M AUM 6.57% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
BMCMI
Bryn Mawr Capital Management Inc Bryn Mawr, Pennsylvania $577M AUM 6.5% 1-Year Est. Return
GACM
Green Arrow Capital Management New York $535M AUM 14.21% 1-Year Est. Return
AH
Achievement Holdings Chicago, Illinois $1.2B AUM 9.2% 1-Year Est. Return

Tamarack Capital Management's Q2 2014 Portfolio in Review

As of Q2 2014, Tamarack Capital Management held 34 positions worth $490M, up 22% from $401M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Tamarack Capital Management deployed $93.4M of net new capital in Q2 2014, opening 10 new positions and adding to 14 existing holdings. Its largest new stake was Aegerion Pharmaceuticals: 400,000 shares worth $11.7M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 44% a quarter earlier, followed by Technology and Real Estate.

On the sell side, the largest reduction was CONMED, an estimated $6.44M trimmed.

  • Tamarack Capital Management's largest Q2 2014 buy was Aegerion Pharmaceuticals: 400,000 shares worth $11.7M.
  • Tamarack Capital Management added most to Spectranetics Corp in Q2 2014, an estimated $14.5M increase.
  • Tamarack Capital Management's biggest Q2 2014 reduction was CONMED, cutting an estimated $6.44M.
  • Tamarack Capital Management fully exited Insys Therapeutics, Inc. in Q2 2014, selling an estimated $19.8M.
  • Tamarack Capital Management's ten largest holdings make up 73% of its $490M portfolio in Q2 2014.
  • Tamarack Capital Management opened 10 new positions and closed 5 in Q2 2014.
  • Tamarack Capital Management's portfolio value rose 22% quarter-over-quarter to $490M.

Based on Tamarack Capital Management's 13F filing for Q2 2014, filed 15 Aug 2014.